Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02579876 · ClinicalTrials.gov registry record · Phase 2

Milk Patch for Eosinophilic Esophagitis

A Phase 2 study, sponsored by Children's Hospital of Philadelphia.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target

NCT02579876 is a Phase 2 study that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02579876, a Phase 2 study, has completed, sponsored by Children's Hospital of Philadelphia.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

This is a single-site, double-blind, placebo-controlled, randomized trial to study efficacy and safety of the Viaskin® Milk Patch for children with milk induced Eosinophilic Esophagitis (EoE). 20 subjects will be randomized 3:1 to Viaskin® Milk or placebo patch.

Interventions

  • DRUG Viaskin Milk 500 mcg
  • DRUG Viaskin Placebo

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2015-10
Est. Completion 2018-11-20
Phase Phase 2

Sponsor

Children's Hospital of Philadelphia

431 total trials

What the Registry Record Tells You About NCT02579876

The ClinicalTrials.gov registry entry for NCT02579876 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Viaskin Milk 500 mcg is the first listed.

NCT02579876 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02579876 about?

NCT02579876 is a clinical study titled "Milk Patch for Eosinophilic Esophagitis". This is a single-site, double-blind, placebo-controlled, randomized trial to study efficacy and safety of the Viaskin® Milk Patch for children with milk induced Eosinophilic Esophagitis (EoE). 20 subjects will be randomized 3:1 to Viaskin® Milk or placebo patch.

What is the current status of trial NCT02579876?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2015-10. Estimated completion is 2018-11-20.

What interventions are being tested in trial NCT02579876?

The interventions under investigation include: Viaskin Milk 500 mcg (DRUG), Viaskin Placebo (DRUG).

Who is sponsoring clinical trial NCT02579876?

This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.